J&J Files For Authorization Of COVID-19 Vaccine Booster

Johnson & Johnson says it had submitted data to the U.S. Food and Drug Administration for emergency use authorization of a booster shot of its COVID-19 vaccine in people aged 18 years and older.<br />J&J says its submission includes data from a late-stage study that found a booster of its vaccine given 56 days after the primary dose provided 94% protection against symptomatic COVID-19 in the United States and 100% protection against severe disease, at least 14 days after the booster shot.<br />The FDA has already authorized a booster dose of the vaccine developed by Pfizer Inc and partner BioNTech for 65-year olds and older, people at high risk of severe disease and others who are regularly exposed to the virus.